These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31887776)

  • 1. Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A.
    Tiede A; Cid AR; Goldmann G; Jiménez-Yuste V; Pluta M; Lissitchkov T; May M; Matytsina I; Miljic P; Pabinger I; Persson P
    Thromb Haemost; 2020 Feb; 120(2):277-288. PubMed ID: 31887776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients.
    van Moort I; Preijers T; Hazendonk HCAM; Schutgens REG; Laros-van Gorkom BAP; Nieuwenhuizen L; van der Meer FJM; Fijnvandraat K; Leebeek FWG; Meijer K; Mathôt RAA; Cnossen MH;
    Br J Clin Pharmacol; 2021 Jun; 87(6):2602-2613. PubMed ID: 33232535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
    Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
    J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of being overweight on factor VIII dosing in children with haemophilia A.
    Henrard S; Hermans C
    Haemophilia; 2016 May; 22(3):361-7. PubMed ID: 26558443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor VIII concentrate dosing with lean body mass, ideal body weight and total body weight in overweight and obesity: A randomized, controlled, open-label, 3 × 3 crossover trial.
    Seaman CD; Yabes JG; Lalama CM; Ragni MV
    Haemophilia; 2021 May; 27(3):351-357. PubMed ID: 33749970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic analysis of anti-hemophilic factor in the obese patient.
    Graham A; Jaworski K
    Haemophilia; 2014 Mar; 20(2):226-9. PubMed ID: 24252161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A.
    Henrard S; Speybroeck N; Hermans C
    J Thromb Haemost; 2011 Sep; 9(9):1784-90. PubMed ID: 21729239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
    Tosetto A; Neff A; Lentz SR; Santagostino E; Nemes L; Sathar J; Meijer K; Chowdary P; Shen C; Landorph A; Hampton K
    Haemophilia; 2020 May; 26(3):450-458. PubMed ID: 32293786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.
    Björkman S; Folkesson A; Jönsson S
    Eur J Clin Pharmacol; 2009 Oct; 65(10):989-98. PubMed ID: 19557401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.
    Delavenne X; Dargaud Y; Ollier E; Négrier C
    Br J Clin Pharmacol; 2019 Apr; 85(4):771-781. PubMed ID: 30633808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extremes of body mass index and postoperative complications after esophagectomy.
    Wightman SC; Posner MC; Patti MG; Ganai S; Watson S; Prachand V; Ferguson MK
    Dis Esophagus; 2017 May; 30(5):1-6. PubMed ID: 28375438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
    Preijers T; van Moort I; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA;
    Thromb Haemost; 2018 Mar; 118(3):514-525. PubMed ID: 29534249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
    Björkman S; Blanchette VS; Fischer K; Oh M; Spotts G; Schroth P; Fritsch S; Patrone L; Ewenstein BM; ; Collins PW
    J Thromb Haemost; 2010 Apr; 8(4):730-6. PubMed ID: 20398185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target.
    Schütte LM; de Rooij N; Hazendonk HCAM; Mathôt RAA; van Hest RM; Leebeek FWG; Cnossen MH; Kruip MJHA
    Haemophilia; 2019 Nov; 25(6):960-968. PubMed ID: 31487098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do acute hospitalised patients in Australia have a different body mass index to the general Australian population: a point prevalence study?
    Dennis DM; Carter V; Trevenen M; Tyler J; Perrella L; Lori E; Cooper I
    Aust Health Rev; 2018 Apr; 42(2):121-129. PubMed ID: 28225703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients.
    Henrard S; Speybroeck N; Hermans C
    Haematologica; 2013 Sep; 98(9):1481-6. PubMed ID: 23645693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PK-guided personalized prophylaxis with Nuwiq
    Lissitchkov T; Rusen L; Georgiev P; Windyga J; Klamroth R; Gercheva L; Nemes L; Tiede A; Bichler J; Knaub S; Belyanskaya L; Walter O; Pasi KJ
    Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity and dental caries in paediatric patients. A cross-sectional study.
    Costacurta M; Di Renzo L; Bianchi A; Fabiocchi F; De Lorenzo A; Docimo R
    Eur J Paediatr Dent; 2011 Jun; 12(2):112-6. PubMed ID: 21668283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.